Baidu
map

Cell:中国学者找到抑制癌变的基因活性“开关”,未来有望作为新药靶点

2016-04-08 澎湃新闻 澎湃新闻

“经过5年的努力 ,基因活性调控的开关终于找到了,肺癌、乳腺癌等困扰人们健康的癌症治疗有了新思路。”近日,复旦大学生物医学研究院(IBS)蓝斐教授兴奋说:“乐观地估计,再过5年左右,根据这一研究而研制出的新药将会上市。” 复旦大学生物医学研究院(IBS)蓝斐教授实验室和施扬教授-石雨江教授实验室合作取得的这一最前沿的新发现,于4月7日被全世界最权威的三大学术杂志之一的Cell杂志刊发。

“经过5年的努力 ,基因活性调控的开关终于找到了,肺癌、乳腺癌等困扰人们健康的癌症治疗有了新思路。”近日,复旦大学生物医学研究院(IBS)蓝斐教授兴奋说:“乐观地估计,再过5年左右,根据这一研究而研制出的新药将会上市。”

复旦大学生物医学研究院(IBS)蓝斐教授实验室和施扬教授-石雨江教授实验室合作取得的这一最前沿的新发现,于4月7日被全世界最权威的三大学术杂志之一的Cell杂志刊发。

上述研究发现,在癌细胞中,染色质中的增强子失控,会过度强化附近癌基因的活性,导致细胞异常甚至癌变。研究同时发现,出现在该区域的蛋白质RACK7和去甲基化酶KDM5C可以限制此类增强子的活性,使基因表达保持在正常范围,从而抑制癌变。

基因突变并非生物体性状改变唯一原因

半个多世纪前,科学家发现了DNA(脱氧核糖核酸)作为细胞中主要遗传物质的基础,开启了分子生物学的时代。DNA上携带着遗传信息的片段,通常被称为基因。

在漫长的进化过程中,DNA序列发生着缓慢的变异以适应着环境的变化。在很长一段时间里,学界依据达尔文的学说,认为生物体的性状改变是由于基因突变和自然选择造成的,这样的改变剧烈且不可逆转。

然而,真实情况下,生物体适应外部环境的速度远高于基因突变速度,这说明很多生物学现象的变化速率远高于DNA的变化频率,仅靠DNA序列本身无法完全应付外部环境变化。

事实上,作为遗传物质载体的染色质上还有另一种物质——组蛋白。组蛋白缠绕着DNA链,支撑和保护着DNA。它们在稳固基因组的同时,也调控着基因的表达:通过改变相关因子的活性来改变DNA信号的释放,控制遗传数据库的输出,进而调控生物体的外在性状。

Figure thumbnail fx1

过去,学界普遍认为,组蛋白的作用就是稳定DNA,不具太多研究价值。直到上世纪90年代末,研究者发现组蛋白上的化学修饰可能具备开关功能,能够控制基因的活性,组蛋白修饰的重要性才因此被确定。

为基因活性找到调控“开关”

蓝斐教授研究团队和施扬教授-石雨江教授研究团队的此次发现,就好比在组蛋白上为基因活性找到了一个调控“开关”。

组蛋白甲基化是一种普遍而关键的修饰形式,它的功能就像是为DNA“贴标签”,来告诉基因组一段段特定的DNA序列如何编码、有什么作用。此次研究的对象——发生在组蛋白H3第4位赖氨酸(H3K4)上的甲基化,就是用来标记该区段DNA活性的。该赖氨酸可出现多种甲基化状态,一般认为其高甲基化态(H3K4me3)出现在基因的起始区,而低甲基化态(H3K4me1)则标记着增强子区。增强子虽然本身不是基因,但是对附近基因活性调节至关重要,增强子失控可直接导致其附近基因活性失控。

复旦大学的这项研究意外的发现,H3K4me3也能发生在增强子区,标记着增强子的过度活化状态,并增强附近的癌基因活性和细胞转移能力,易造成癌变。研究组顺藤摸瓜,找到了一种名为RACK7的蛋白质,它可以吸引名为KDM5C的组蛋白去甲基化酶,将原本的高甲基化状态转化成低甲基化状态,使周围的基因表达保持在正常范围,从而阻止细胞癌变。

增强子活性调控机制可应用于癌症治疗

据蓝斐介绍,这项研究早在2011年就已启动,起初进展并不顺利,“这个RACK7蛋白像是藏于通幽曲径之中,我们知道那背后是壮丽的奇景,但始终不能得窥门径”。直到2014年初,本论文的共同第一作者生物医学研究院博士后沈宏杰和博士生徐文绮意外地发现“增强子过度活化态”并证明其与RACK7之间存在关联,这才“摸准了脉”,之后的研究也水到渠成。

实际上,由于改变增强子活性比改变基因序列更容易实现,因此具备极大的应用前景,它已成为近年来表观遗传领域的一项研究热点。只是在这项新发现以前,学界未意识到H3K4的甲基化动态变化发生在增强子上,因而并未发现该调控的具体机制。

值得一提的是,复旦、哈佛双聘教授施扬正是组蛋白去甲基化领域的奠基人和开拓者之一。早在2004-2007年间,他与当时还在其实验室开展研究的石雨江博士后和蓝斐博士在国际上发现了首例组蛋白去甲基化酶LSD1和其它多类去甲基化酶,包括本项研究涉及到的KDM5C。去甲基化酶的发现,不仅证明了组蛋白甲基化是可逆的,也为甲基化修饰参与基因活性的动态调控奠定了理论基础。

12年后,蓝斐教授研究团队和施扬教授-石雨江教授研究团队的这项发现,又将该领域的研究向前推进了一步。蓝斐笑言:“那时候只知道组蛋白甲基化是基因组上的‘标签’,‘标签’可贴上也可以撕去,但是很多‘标签’的具体功能并不清楚。通过这些年的积累,已经知道越来越多的‘标签’是在做什么的,还知道是哪些因子在什么情况下在‘贴’和‘撕’它们的了。”

这项发现,不仅发现了表观遗传修饰对基因组信息进行自我调节的新规律、提出了“增强子过度活化态”理论,更重要的是它潜在的医疗价值:很多癌症病例中存在RACK7和KDM5C突变现象,无法对增强子活性进行限制,使得本应保持低活性的基因异常活化。如今这一机制被揭示,不仅对癌症发生提供了一种新的理论解释,更可为癌症的个性化治疗提供新的药物靶点和治疗思路。

原始出处:
Hongjie Shen7, Wenqi Xu7, Rui Guo, Bowen Rong, Lei Gu, Zhentian Wang, Chenxi He, Lijuan Zheng, Xin Hu, Zhen Hu, Zhi-Ming Shao, Pengyuan Yang, Feizhen Wu, Yujiang Geno Shi, Yang Shi, Fei Lan.Suppression of Enhancer Overactivation by a RACK7-Histone Demethylase Complex. DOI: http://dx.doi.org/10.1016/j.cell.2016.02.064

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (18)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1959588, encodeId=9535195958815, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Mon Apr 18 20:15:00 CST 2016, time=2016-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=139447, encodeId=ad9a13944eef, content=深度好文,值得关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Mon Oct 03 09:42:53 CST 2016, time=2016-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2066524, encodeId=cdd32066524e1, content=<a href='/topic/show?id=425e41e8523' target=_blank style='color:#2F92EE;'>#基因活性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41785, encryptionId=425e41e8523, topicName=基因活性)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/7F67E3BE360D6DD1D0A62E3E71E23CB6/100, createdBy=9d8a2500148, createdName=ms8888626721583891, createdTime=Wed Jun 15 02:15:00 CST 2016, time=2016-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869331, encodeId=d94f18693312b, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Jul 03 12:15:00 CST 2016, time=2016-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78171, encodeId=eb12e817176, content=值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Thu Apr 14 18:39:00 CST 2016, time=2016-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78170, encodeId=cbf6e8170fa, content=文章不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Thu Apr 14 18:39:00 CST 2016, time=2016-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=77401, encodeId=7e59e74013d, content=期待新药早日研发, beContent=null, objectType=article, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/PiajxSqBRaEJJAFMgSjibMicGVUgkmDBw4svXiccQxZicwjRHNxGPTghAmITxP12Rcmm0yFKfwGwUaiaUwpPUUUTOd2g/0, createdBy=fcd21609070, createdName=hekzn, createdTime=Mon Apr 11 10:42:00 CST 2016, time=2016-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=77400, encodeId=c8c2e740094, content=学习了 长知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/PiajxSqBRaEJJAFMgSjibMicGVUgkmDBw4svXiccQxZicwjRHNxGPTghAmITxP12Rcmm0yFKfwGwUaiaUwpPUUUTOd2g/0, createdBy=fcd21609070, createdName=hekzn, createdTime=Mon Apr 11 10:41:00 CST 2016, time=2016-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=77330, encodeId=58fde73302a, content=谢谢,学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=161, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73801651090, createdName=1ddc978cm67(暂无匿称), createdTime=Mon Apr 11 05:52:00 CST 2016, time=2016-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=76668, encodeId=f61be66681a, content=希望个性化医疗蓬勃发展, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0e051704922, createdName=1de8cec4m66(暂无匿称), createdTime=Sun Apr 10 13:34:00 CST 2016, time=2016-04-10, status=1, ipAttribution=)]
    2016-04-18 维他命
  2. [GetPortalCommentsPageByObjectIdResponse(id=1959588, encodeId=9535195958815, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Mon Apr 18 20:15:00 CST 2016, time=2016-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=139447, encodeId=ad9a13944eef, content=深度好文,值得关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Mon Oct 03 09:42:53 CST 2016, time=2016-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2066524, encodeId=cdd32066524e1, content=<a href='/topic/show?id=425e41e8523' target=_blank style='color:#2F92EE;'>#基因活性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41785, encryptionId=425e41e8523, topicName=基因活性)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/7F67E3BE360D6DD1D0A62E3E71E23CB6/100, createdBy=9d8a2500148, createdName=ms8888626721583891, createdTime=Wed Jun 15 02:15:00 CST 2016, time=2016-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869331, encodeId=d94f18693312b, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Jul 03 12:15:00 CST 2016, time=2016-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78171, encodeId=eb12e817176, content=值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Thu Apr 14 18:39:00 CST 2016, time=2016-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78170, encodeId=cbf6e8170fa, content=文章不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Thu Apr 14 18:39:00 CST 2016, time=2016-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=77401, encodeId=7e59e74013d, content=期待新药早日研发, beContent=null, objectType=article, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/PiajxSqBRaEJJAFMgSjibMicGVUgkmDBw4svXiccQxZicwjRHNxGPTghAmITxP12Rcmm0yFKfwGwUaiaUwpPUUUTOd2g/0, createdBy=fcd21609070, createdName=hekzn, createdTime=Mon Apr 11 10:42:00 CST 2016, time=2016-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=77400, encodeId=c8c2e740094, content=学习了 长知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/PiajxSqBRaEJJAFMgSjibMicGVUgkmDBw4svXiccQxZicwjRHNxGPTghAmITxP12Rcmm0yFKfwGwUaiaUwpPUUUTOd2g/0, createdBy=fcd21609070, createdName=hekzn, createdTime=Mon Apr 11 10:41:00 CST 2016, time=2016-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=77330, encodeId=58fde73302a, content=谢谢,学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=161, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73801651090, createdName=1ddc978cm67(暂无匿称), createdTime=Mon Apr 11 05:52:00 CST 2016, time=2016-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=76668, encodeId=f61be66681a, content=希望个性化医疗蓬勃发展, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0e051704922, createdName=1de8cec4m66(暂无匿称), createdTime=Sun Apr 10 13:34:00 CST 2016, time=2016-04-10, status=1, ipAttribution=)]
    2016-10-03 1e10c84am36(暂无匿称)

    深度好文,值得关注

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1959588, encodeId=9535195958815, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Mon Apr 18 20:15:00 CST 2016, time=2016-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=139447, encodeId=ad9a13944eef, content=深度好文,值得关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Mon Oct 03 09:42:53 CST 2016, time=2016-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2066524, encodeId=cdd32066524e1, content=<a href='/topic/show?id=425e41e8523' target=_blank style='color:#2F92EE;'>#基因活性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41785, encryptionId=425e41e8523, topicName=基因活性)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/7F67E3BE360D6DD1D0A62E3E71E23CB6/100, createdBy=9d8a2500148, createdName=ms8888626721583891, createdTime=Wed Jun 15 02:15:00 CST 2016, time=2016-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869331, encodeId=d94f18693312b, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Jul 03 12:15:00 CST 2016, time=2016-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78171, encodeId=eb12e817176, content=值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Thu Apr 14 18:39:00 CST 2016, time=2016-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78170, encodeId=cbf6e8170fa, content=文章不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Thu Apr 14 18:39:00 CST 2016, time=2016-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=77401, encodeId=7e59e74013d, content=期待新药早日研发, beContent=null, objectType=article, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/PiajxSqBRaEJJAFMgSjibMicGVUgkmDBw4svXiccQxZicwjRHNxGPTghAmITxP12Rcmm0yFKfwGwUaiaUwpPUUUTOd2g/0, createdBy=fcd21609070, createdName=hekzn, createdTime=Mon Apr 11 10:42:00 CST 2016, time=2016-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=77400, encodeId=c8c2e740094, content=学习了 长知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/PiajxSqBRaEJJAFMgSjibMicGVUgkmDBw4svXiccQxZicwjRHNxGPTghAmITxP12Rcmm0yFKfwGwUaiaUwpPUUUTOd2g/0, createdBy=fcd21609070, createdName=hekzn, createdTime=Mon Apr 11 10:41:00 CST 2016, time=2016-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=77330, encodeId=58fde73302a, content=谢谢,学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=161, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73801651090, createdName=1ddc978cm67(暂无匿称), createdTime=Mon Apr 11 05:52:00 CST 2016, time=2016-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=76668, encodeId=f61be66681a, content=希望个性化医疗蓬勃发展, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0e051704922, createdName=1de8cec4m66(暂无匿称), createdTime=Sun Apr 10 13:34:00 CST 2016, time=2016-04-10, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1959588, encodeId=9535195958815, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Mon Apr 18 20:15:00 CST 2016, time=2016-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=139447, encodeId=ad9a13944eef, content=深度好文,值得关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Mon Oct 03 09:42:53 CST 2016, time=2016-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2066524, encodeId=cdd32066524e1, content=<a href='/topic/show?id=425e41e8523' target=_blank style='color:#2F92EE;'>#基因活性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41785, encryptionId=425e41e8523, topicName=基因活性)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/7F67E3BE360D6DD1D0A62E3E71E23CB6/100, createdBy=9d8a2500148, createdName=ms8888626721583891, createdTime=Wed Jun 15 02:15:00 CST 2016, time=2016-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869331, encodeId=d94f18693312b, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Jul 03 12:15:00 CST 2016, time=2016-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78171, encodeId=eb12e817176, content=值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Thu Apr 14 18:39:00 CST 2016, time=2016-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78170, encodeId=cbf6e8170fa, content=文章不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Thu Apr 14 18:39:00 CST 2016, time=2016-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=77401, encodeId=7e59e74013d, content=期待新药早日研发, beContent=null, objectType=article, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/PiajxSqBRaEJJAFMgSjibMicGVUgkmDBw4svXiccQxZicwjRHNxGPTghAmITxP12Rcmm0yFKfwGwUaiaUwpPUUUTOd2g/0, createdBy=fcd21609070, createdName=hekzn, createdTime=Mon Apr 11 10:42:00 CST 2016, time=2016-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=77400, encodeId=c8c2e740094, content=学习了 长知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/PiajxSqBRaEJJAFMgSjibMicGVUgkmDBw4svXiccQxZicwjRHNxGPTghAmITxP12Rcmm0yFKfwGwUaiaUwpPUUUTOd2g/0, createdBy=fcd21609070, createdName=hekzn, createdTime=Mon Apr 11 10:41:00 CST 2016, time=2016-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=77330, encodeId=58fde73302a, content=谢谢,学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=161, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73801651090, createdName=1ddc978cm67(暂无匿称), createdTime=Mon Apr 11 05:52:00 CST 2016, time=2016-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=76668, encodeId=f61be66681a, content=希望个性化医疗蓬勃发展, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0e051704922, createdName=1de8cec4m66(暂无匿称), createdTime=Sun Apr 10 13:34:00 CST 2016, time=2016-04-10, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1959588, encodeId=9535195958815, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Mon Apr 18 20:15:00 CST 2016, time=2016-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=139447, encodeId=ad9a13944eef, content=深度好文,值得关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Mon Oct 03 09:42:53 CST 2016, time=2016-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2066524, encodeId=cdd32066524e1, content=<a href='/topic/show?id=425e41e8523' target=_blank style='color:#2F92EE;'>#基因活性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41785, encryptionId=425e41e8523, topicName=基因活性)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/7F67E3BE360D6DD1D0A62E3E71E23CB6/100, createdBy=9d8a2500148, createdName=ms8888626721583891, createdTime=Wed Jun 15 02:15:00 CST 2016, time=2016-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869331, encodeId=d94f18693312b, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Jul 03 12:15:00 CST 2016, time=2016-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78171, encodeId=eb12e817176, content=值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Thu Apr 14 18:39:00 CST 2016, time=2016-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78170, encodeId=cbf6e8170fa, content=文章不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Thu Apr 14 18:39:00 CST 2016, time=2016-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=77401, encodeId=7e59e74013d, content=期待新药早日研发, beContent=null, objectType=article, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/PiajxSqBRaEJJAFMgSjibMicGVUgkmDBw4svXiccQxZicwjRHNxGPTghAmITxP12Rcmm0yFKfwGwUaiaUwpPUUUTOd2g/0, createdBy=fcd21609070, createdName=hekzn, createdTime=Mon Apr 11 10:42:00 CST 2016, time=2016-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=77400, encodeId=c8c2e740094, content=学习了 长知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/PiajxSqBRaEJJAFMgSjibMicGVUgkmDBw4svXiccQxZicwjRHNxGPTghAmITxP12Rcmm0yFKfwGwUaiaUwpPUUUTOd2g/0, createdBy=fcd21609070, createdName=hekzn, createdTime=Mon Apr 11 10:41:00 CST 2016, time=2016-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=77330, encodeId=58fde73302a, content=谢谢,学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=161, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73801651090, createdName=1ddc978cm67(暂无匿称), createdTime=Mon Apr 11 05:52:00 CST 2016, time=2016-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=76668, encodeId=f61be66681a, content=希望个性化医疗蓬勃发展, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0e051704922, createdName=1de8cec4m66(暂无匿称), createdTime=Sun Apr 10 13:34:00 CST 2016, time=2016-04-10, status=1, ipAttribution=)]
    2016-04-14 李继凯

    值得学习

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1959588, encodeId=9535195958815, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Mon Apr 18 20:15:00 CST 2016, time=2016-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=139447, encodeId=ad9a13944eef, content=深度好文,值得关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Mon Oct 03 09:42:53 CST 2016, time=2016-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2066524, encodeId=cdd32066524e1, content=<a href='/topic/show?id=425e41e8523' target=_blank style='color:#2F92EE;'>#基因活性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41785, encryptionId=425e41e8523, topicName=基因活性)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/7F67E3BE360D6DD1D0A62E3E71E23CB6/100, createdBy=9d8a2500148, createdName=ms8888626721583891, createdTime=Wed Jun 15 02:15:00 CST 2016, time=2016-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869331, encodeId=d94f18693312b, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Jul 03 12:15:00 CST 2016, time=2016-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78171, encodeId=eb12e817176, content=值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Thu Apr 14 18:39:00 CST 2016, time=2016-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78170, encodeId=cbf6e8170fa, content=文章不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Thu Apr 14 18:39:00 CST 2016, time=2016-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=77401, encodeId=7e59e74013d, content=期待新药早日研发, beContent=null, objectType=article, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/PiajxSqBRaEJJAFMgSjibMicGVUgkmDBw4svXiccQxZicwjRHNxGPTghAmITxP12Rcmm0yFKfwGwUaiaUwpPUUUTOd2g/0, createdBy=fcd21609070, createdName=hekzn, createdTime=Mon Apr 11 10:42:00 CST 2016, time=2016-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=77400, encodeId=c8c2e740094, content=学习了 长知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/PiajxSqBRaEJJAFMgSjibMicGVUgkmDBw4svXiccQxZicwjRHNxGPTghAmITxP12Rcmm0yFKfwGwUaiaUwpPUUUTOd2g/0, createdBy=fcd21609070, createdName=hekzn, createdTime=Mon Apr 11 10:41:00 CST 2016, time=2016-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=77330, encodeId=58fde73302a, content=谢谢,学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=161, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73801651090, createdName=1ddc978cm67(暂无匿称), createdTime=Mon Apr 11 05:52:00 CST 2016, time=2016-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=76668, encodeId=f61be66681a, content=希望个性化医疗蓬勃发展, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0e051704922, createdName=1de8cec4m66(暂无匿称), createdTime=Sun Apr 10 13:34:00 CST 2016, time=2016-04-10, status=1, ipAttribution=)]
    2016-04-14 李继凯

    文章不错

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1959588, encodeId=9535195958815, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Mon Apr 18 20:15:00 CST 2016, time=2016-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=139447, encodeId=ad9a13944eef, content=深度好文,值得关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Mon Oct 03 09:42:53 CST 2016, time=2016-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2066524, encodeId=cdd32066524e1, content=<a href='/topic/show?id=425e41e8523' target=_blank style='color:#2F92EE;'>#基因活性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41785, encryptionId=425e41e8523, topicName=基因活性)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/7F67E3BE360D6DD1D0A62E3E71E23CB6/100, createdBy=9d8a2500148, createdName=ms8888626721583891, createdTime=Wed Jun 15 02:15:00 CST 2016, time=2016-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869331, encodeId=d94f18693312b, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Jul 03 12:15:00 CST 2016, time=2016-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78171, encodeId=eb12e817176, content=值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Thu Apr 14 18:39:00 CST 2016, time=2016-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78170, encodeId=cbf6e8170fa, content=文章不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Thu Apr 14 18:39:00 CST 2016, time=2016-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=77401, encodeId=7e59e74013d, content=期待新药早日研发, beContent=null, objectType=article, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/PiajxSqBRaEJJAFMgSjibMicGVUgkmDBw4svXiccQxZicwjRHNxGPTghAmITxP12Rcmm0yFKfwGwUaiaUwpPUUUTOd2g/0, createdBy=fcd21609070, createdName=hekzn, createdTime=Mon Apr 11 10:42:00 CST 2016, time=2016-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=77400, encodeId=c8c2e740094, content=学习了 长知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/PiajxSqBRaEJJAFMgSjibMicGVUgkmDBw4svXiccQxZicwjRHNxGPTghAmITxP12Rcmm0yFKfwGwUaiaUwpPUUUTOd2g/0, createdBy=fcd21609070, createdName=hekzn, createdTime=Mon Apr 11 10:41:00 CST 2016, time=2016-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=77330, encodeId=58fde73302a, content=谢谢,学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=161, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73801651090, createdName=1ddc978cm67(暂无匿称), createdTime=Mon Apr 11 05:52:00 CST 2016, time=2016-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=76668, encodeId=f61be66681a, content=希望个性化医疗蓬勃发展, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0e051704922, createdName=1de8cec4m66(暂无匿称), createdTime=Sun Apr 10 13:34:00 CST 2016, time=2016-04-10, status=1, ipAttribution=)]
    2016-04-11 hekzn

    期待新药早日研发

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1959588, encodeId=9535195958815, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Mon Apr 18 20:15:00 CST 2016, time=2016-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=139447, encodeId=ad9a13944eef, content=深度好文,值得关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Mon Oct 03 09:42:53 CST 2016, time=2016-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2066524, encodeId=cdd32066524e1, content=<a href='/topic/show?id=425e41e8523' target=_blank style='color:#2F92EE;'>#基因活性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41785, encryptionId=425e41e8523, topicName=基因活性)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/7F67E3BE360D6DD1D0A62E3E71E23CB6/100, createdBy=9d8a2500148, createdName=ms8888626721583891, createdTime=Wed Jun 15 02:15:00 CST 2016, time=2016-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869331, encodeId=d94f18693312b, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Jul 03 12:15:00 CST 2016, time=2016-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78171, encodeId=eb12e817176, content=值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Thu Apr 14 18:39:00 CST 2016, time=2016-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78170, encodeId=cbf6e8170fa, content=文章不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Thu Apr 14 18:39:00 CST 2016, time=2016-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=77401, encodeId=7e59e74013d, content=期待新药早日研发, beContent=null, objectType=article, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/PiajxSqBRaEJJAFMgSjibMicGVUgkmDBw4svXiccQxZicwjRHNxGPTghAmITxP12Rcmm0yFKfwGwUaiaUwpPUUUTOd2g/0, createdBy=fcd21609070, createdName=hekzn, createdTime=Mon Apr 11 10:42:00 CST 2016, time=2016-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=77400, encodeId=c8c2e740094, content=学习了 长知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/PiajxSqBRaEJJAFMgSjibMicGVUgkmDBw4svXiccQxZicwjRHNxGPTghAmITxP12Rcmm0yFKfwGwUaiaUwpPUUUTOd2g/0, createdBy=fcd21609070, createdName=hekzn, createdTime=Mon Apr 11 10:41:00 CST 2016, time=2016-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=77330, encodeId=58fde73302a, content=谢谢,学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=161, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73801651090, createdName=1ddc978cm67(暂无匿称), createdTime=Mon Apr 11 05:52:00 CST 2016, time=2016-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=76668, encodeId=f61be66681a, content=希望个性化医疗蓬勃发展, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0e051704922, createdName=1de8cec4m66(暂无匿称), createdTime=Sun Apr 10 13:34:00 CST 2016, time=2016-04-10, status=1, ipAttribution=)]
    2016-04-11 hekzn

    学习了 长知识

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1959588, encodeId=9535195958815, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Mon Apr 18 20:15:00 CST 2016, time=2016-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=139447, encodeId=ad9a13944eef, content=深度好文,值得关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Mon Oct 03 09:42:53 CST 2016, time=2016-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2066524, encodeId=cdd32066524e1, content=<a href='/topic/show?id=425e41e8523' target=_blank style='color:#2F92EE;'>#基因活性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41785, encryptionId=425e41e8523, topicName=基因活性)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/7F67E3BE360D6DD1D0A62E3E71E23CB6/100, createdBy=9d8a2500148, createdName=ms8888626721583891, createdTime=Wed Jun 15 02:15:00 CST 2016, time=2016-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869331, encodeId=d94f18693312b, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Jul 03 12:15:00 CST 2016, time=2016-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78171, encodeId=eb12e817176, content=值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Thu Apr 14 18:39:00 CST 2016, time=2016-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78170, encodeId=cbf6e8170fa, content=文章不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Thu Apr 14 18:39:00 CST 2016, time=2016-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=77401, encodeId=7e59e74013d, content=期待新药早日研发, beContent=null, objectType=article, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/PiajxSqBRaEJJAFMgSjibMicGVUgkmDBw4svXiccQxZicwjRHNxGPTghAmITxP12Rcmm0yFKfwGwUaiaUwpPUUUTOd2g/0, createdBy=fcd21609070, createdName=hekzn, createdTime=Mon Apr 11 10:42:00 CST 2016, time=2016-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=77400, encodeId=c8c2e740094, content=学习了 长知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/PiajxSqBRaEJJAFMgSjibMicGVUgkmDBw4svXiccQxZicwjRHNxGPTghAmITxP12Rcmm0yFKfwGwUaiaUwpPUUUTOd2g/0, createdBy=fcd21609070, createdName=hekzn, createdTime=Mon Apr 11 10:41:00 CST 2016, time=2016-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=77330, encodeId=58fde73302a, content=谢谢,学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=161, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73801651090, createdName=1ddc978cm67(暂无匿称), createdTime=Mon Apr 11 05:52:00 CST 2016, time=2016-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=76668, encodeId=f61be66681a, content=希望个性化医疗蓬勃发展, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0e051704922, createdName=1de8cec4m66(暂无匿称), createdTime=Sun Apr 10 13:34:00 CST 2016, time=2016-04-10, status=1, ipAttribution=)]
    2016-04-11 1ddc978cm67(暂无匿称)

    谢谢,学习了。

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=1959588, encodeId=9535195958815, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Mon Apr 18 20:15:00 CST 2016, time=2016-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=139447, encodeId=ad9a13944eef, content=深度好文,值得关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Mon Oct 03 09:42:53 CST 2016, time=2016-10-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2066524, encodeId=cdd32066524e1, content=<a href='/topic/show?id=425e41e8523' target=_blank style='color:#2F92EE;'>#基因活性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=41785, encryptionId=425e41e8523, topicName=基因活性)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/7F67E3BE360D6DD1D0A62E3E71E23CB6/100, createdBy=9d8a2500148, createdName=ms8888626721583891, createdTime=Wed Jun 15 02:15:00 CST 2016, time=2016-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1869331, encodeId=d94f18693312b, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Jul 03 12:15:00 CST 2016, time=2016-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78171, encodeId=eb12e817176, content=值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Thu Apr 14 18:39:00 CST 2016, time=2016-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78170, encodeId=cbf6e8170fa, content=文章不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Thu Apr 14 18:39:00 CST 2016, time=2016-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=77401, encodeId=7e59e74013d, content=期待新药早日研发, beContent=null, objectType=article, channel=null, level=null, likeNumber=132, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/PiajxSqBRaEJJAFMgSjibMicGVUgkmDBw4svXiccQxZicwjRHNxGPTghAmITxP12Rcmm0yFKfwGwUaiaUwpPUUUTOd2g/0, createdBy=fcd21609070, createdName=hekzn, createdTime=Mon Apr 11 10:42:00 CST 2016, time=2016-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=77400, encodeId=c8c2e740094, content=学习了 长知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/PiajxSqBRaEJJAFMgSjibMicGVUgkmDBw4svXiccQxZicwjRHNxGPTghAmITxP12Rcmm0yFKfwGwUaiaUwpPUUUTOd2g/0, createdBy=fcd21609070, createdName=hekzn, createdTime=Mon Apr 11 10:41:00 CST 2016, time=2016-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=77330, encodeId=58fde73302a, content=谢谢,学习了。, beContent=null, objectType=article, channel=null, level=null, likeNumber=161, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73801651090, createdName=1ddc978cm67(暂无匿称), createdTime=Mon Apr 11 05:52:00 CST 2016, time=2016-04-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=76668, encodeId=f61be66681a, content=希望个性化医疗蓬勃发展, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0e051704922, createdName=1de8cec4m66(暂无匿称), createdTime=Sun Apr 10 13:34:00 CST 2016, time=2016-04-10, status=1, ipAttribution=)]
    2016-04-10 1de8cec4m66(暂无匿称)

    希望个性化医疗蓬勃发展

    0

相关资讯

PLOS Genetics:唇腭裂发生的新基因被发现

PLOS Genetics:科学家发现唇腭裂发生的新基因 非综合征性唇腭裂是一种常见的出生缺陷,病因较多且复杂。其最常见的类型是唇裂(nsCLP),伴或不伴有腭裂(nsCLO)。虽然遗传因素在人类唇腭裂的发生中起着重要作用,但是遗传因素在腭裂发生过程中的重要性却并不清楚。本研究中,研究人员从三个大型队列研究中提取了遗传和临床数据进行荟萃分析,并确定了染色体15q13上的一个区域与唇腭裂的发生之间密

Neuron:睡不着?说明你缺钙

最近一项研究指出,多食富含钙的食品有助于睡眠。 日本东京大学的研究人员指出,钙对保持机体的骨骼和牙齿健康及自身强壮具有重要作用,对存在睡眠剥夺的民众而言也有一定的好处。通过深入探究民众睡眠的完整过程后,研究人员发现,慢波睡眠的质量取决于机体大脑细胞或神经元内钙的活性。 东京大学的Hiroki Ueda教授指出,虽然睡眠是人类的基本生理功能,但我们对其机制仍然知之甚少。通过使用各种科学技术、计算机模

JMCB:基因编辑猪可分泌人胰岛素

中国科学院广州生物医药与健康研究院赖良学课题组,利用精确基因编辑技术对猪胰岛素基因进行了无痕定点修饰,使猪胰岛素基因编码生产人胰岛素,建立了完全分泌人胰岛素的基因编辑猪。相关成果日前在线发表于《分子细胞生物学杂志》。 目前,对糖尿病的治疗包括胰岛素注射和胰岛移植。利用猪胰岛进行异种移植治疗糖尿病已取得良好进展。但猪与人相比,胰岛素蛋白存在一个氨基酸的差异,这使猪胰岛素在人体中的降血糖效价较

Circulation:家族性高胆固醇血症的发病率超过你相信(NHANES研究)

近期发表在Circulation的研究称,当前250个美国人中就有1人患有家族性高胆固醇血症(FH)。该数据是先前普遍认同发病率的2倍!哈佛大学医学院的儿科心脏病学副教授、波士顿儿童医院预防心脏病学主任Sarah de Ferranti博士说:“该数据比我们想象中的更常见,并且年轻人患上FH应该得到重任,该疾病常常在出现严重心脏病之前,都不会有任何症状。一个三四十岁的患者,就算看起来很健康,吃得好

BMJ:当你知道你的基因会给你带来疾病时,你会改变自己的行为吗?

研究者检索了Medline、Embase、PsycINFO等数据库,纳入基于个体化DNA进行疾病风险评估,以及通过行为方式降低风险的相关研究,进行系统回顾和荟萃分析,以评估健康行为方式对基于DNA的疾病风险的影响。最终纳入了18篇研究涉及7种行为方式,包括戒烟(6篇研究,n=2663)、饮食(7篇研究,n=1784)和运动(6篇研究,n=1704)。荟萃分析结果显示基于DNA的疾病风险对戒烟、饮食

Nature Genetics:全球研究揭示基因作为炎性疾病的主要原因

一项50家不同研究中心参与的全球研究发现了数百个导致5种常见、难治炎性疾病的基因,为开发这些疾病的新疗法铺平了道路。 这项研究由澳大利亚昆士兰科技大学(QUT)和德国基尔大学(Christian-Albrechts-University)领导,最新发表于国际期刊《Nature Genetics》。 该研究共同资深作者、QUT健康和生物医学创新研究所教授Matthew Brown说,他们研究了强

Baidu
map
Baidu
map
Baidu
map